Launched KOMZIFTI™ (ziftomenib), first and only once-daily, oral menin inhibitor approved for adults with R/R NPM1-mutated ...

Their award-winning projects in the prestigious competition cover topics in the sciences, engineering, social sciences and mathematics.

A small set of common blood biomarkers predicts which older adults will develop specific combinations of chronic diseases - and how quickly, a new study from Karolinska Institutet published in Nature ...

Over 70 percent of patients in the first-line subgroup responded to amivantamab plus chemotherapy with most responses lasting beyond 16 monthsNotable ...

Over 70 percent of patients in the first-line subgroup responded to amivantamab plus chemotherapy with most responses lasting beyond 16 months Notable responses were ...

HealthDay News — Common blood biomarkers can predict multimorbidity, according to a study published online Jan. 2 in Nature ...

Society for Science (the Society) announced the top 300 scholars in the Regeneron Science Talent Search 2026, the nation’s ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced The New England Journal of Medicine (NEJM) published the full results from the positive Phase 3 ASCENT-04/KEYNOTE-D19 study evaluating the ...

Ultrasound-derived VAT demonstrated better predictive ability than BMI and waist circumference in hepato-metabolic assessment in MASLD.

Sarepta Therapeutics, Inc. , the leader in precision genetic medicine for rare diseases, today reports preliminary* fourth quarter and full-year 2025 net product revenues and cash, cash equivalents, ...

Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on January 2 ...